Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to disappointing results from its Phase 2b MASH trial of Pemvidutide, which led to a significant drop in its stock price [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising Altimmune investors to join a class action for those who purchased securities between August 10, 2023, and June 25, 2025 [1]. - Investors have until October 6, 2025, to file a lead plaintiff motion [1]. Group 2: Trial Results and Stock Impact - On June 26, 2025, Altimmune announced that its Phase 2b MASH trial did not achieve statistical significance in the primary endpoint of fibrosis reduction, despite showing a positive trend [3]. - The stock price of Altimmune fell by $4.10, or 53.2%, closing at $3.61 per share following the announcement of the trial results [3]. Group 3: Legal Representation - The Portnoy Law Firm specializes in representing investors in claims related to corporate wrongdoing and has recovered over $5.5 billion for investors in the past [4].